A new strategy: identification of specific antibodies for neutralizing epitope on SARS-CoV-2 S protein by LC-MS/MS combined with immune repertoire.

COVID-19 Neutralizing antibody Neutralizing epitope;LC-MS/MS

Journal

Molecular biomedicine
ISSN: 2662-8651
Titre abrégé: Mol Biomed
Pays: Singapore
ID NLM: 9918283581406676

Informations de publication

Date de publication:
05 Jul 2022
Historique:
received: 11 04 2022
accepted: 30 05 2022
entrez: 5 7 2022
pubmed: 6 7 2022
medline: 6 7 2022
Statut: epublish

Résumé

Although the SARS-CoV-2 vaccine has been widely used worldwide, not all individuals can produce neutralization antibodies, so it is still urgent to find and prepare neutralization antibodies for COVID-19 prevention or treatment. In this study, we created a new strategy to effectively obtain neutralizing antibodies or complementary determining region 3 (CDR3) of neutralizing antibodies against SARS-CoV-2. We first predicted and synthesized several B cell epitopes on RBD and adjacent RBD of S protein, then the B cell epitopes were used to prepare affinity chromatography columns respectively and purify the binding IgG from serum samples of convalescent COVID-19 patients. After these IgGs were identified to have neutralizing activity, the peptide sequences of the antigen-binding regions (variable region) of neutralizing antibodies were analyzed by protein mass spectrometry. Subsequently, the B cells from the same individual were sorted and used to obtain their full BCR repertoire by 5' RACE combined with high-throughput of PacBio sequencing method. Then, the peptide sequence of neutralizing antibody variable region by protein mass spectrometry was mapped to the full BCR repertoire and found the full variable region sequence of neutralizing antibodies. Finally, we obtained and synthesized numerous CDR3 peptides of neutralizing antibodies to confirm the neutralizing activity for SARS-CoV-2 infection. Our results indicate that the novel scheme will be suitable for rapid screening of neutralizing antibodies, including screening neutralizing antibodies against SARS-CoV-2 and other pathogenic microorganisms.

Identifiants

pubmed: 35788448
doi: 10.1186/s43556-022-00085-0
pii: 10.1186/s43556-022-00085-0
pmc: PMC9253215
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20

Subventions

Organisme : Ministry of Science and Technology of the People's Republic of China
ID : 2020YFA0707801
Organisme : National Natural Science Foundation of China
ID : 82030044
Organisme : Discipline Construction Project of Peking University Health Science Center
ID : BMU2020HKYZX004
Organisme : outh Foundation of Chinese PLA General Hospital
ID : QNF19040

Informations de copyright

© 2022. The Author(s).

Références

Elife. 2020 Oct 28;9:
pubmed: 33112236
Cold Spring Harb Protoc. 2011 Jun 01;2011(6):633-42
pubmed: 21632789
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
Nature. 2020 Oct;586(7830):572-577
pubmed: 32726802
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
Nat Commun. 2021 Jan 12;12(1):288
pubmed: 33436577
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018
pubmed: 34982465
Cell. 2020 Jun 25;181(7):1458-1463
pubmed: 32492407
Adv Mater. 2020 Dec;32(50):e2005637
pubmed: 33111375
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
Nature. 2019 Oct;574(7776):122-126
pubmed: 31554970
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
MedComm (2020). 2021 Oct 19;2(4):846-854
pubmed: 34909755
Nucleic Acids Res. 2017 Jul 3;45(W1):W24-W29
pubmed: 28472356
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2022 Jun 2;386(22):2097-2111
pubmed: 35507481

Auteurs

Meng Yu (M)

Department of Immunology, School of Basic Medical Sciences, Peking University, and NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China.

Zhu Zhu (Z)

Department of Immunology, School of Basic Medical Sciences, Peking University, and NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China.

Yanqun Wang (Y)

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Pingzhang Wang (P)

Department of Immunology, School of Basic Medical Sciences, Peking University, and NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China.

Xiaodong Jia (X)

Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

Jie Wang (J)

Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Lei Liu (L)

Department of Transfusion Medicine, General Hospital of Central Theater Command of PLA, Wuhan, Hubei, China.

Wanbing Liu (W)

Department of Transfusion Medicine, General Hospital of Central Theater Command of PLA, Wuhan, Hubei, China.

Yaqiong Zheng (Y)

Department of Transfusion Medicine, General Hospital of Central Theater Command of PLA, Wuhan, Hubei, China.

Guomei Kou (G)

Department of Transfusion Medicine, General Hospital of Central Theater Command of PLA, Wuhan, Hubei, China.

Weiyan Xu (W)

Department of Immunology, School of Basic Medical Sciences, Peking University, and NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China.

Jing Huang (J)

Department of Immunology, School of Basic Medical Sciences, Peking University, and NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China.

Fengmin Lu (F)

Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Xiajuan Zou (X)

Medical and Healthy Analysis Center, Peking University, Beijing, China.

Shangen Zheng (S)

Department of Transfusion Medicine, General Hospital of Central Theater Command of PLA, Wuhan, Hubei, China. sxkzsg@sina.com.

Yinying Lu (Y)

Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. luyinying1973@163.com.

Jincun Zhao (J)

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. zhaojincun@gird.cn.

Hui Dai (H)

Department of Immunology, School of Basic Medical Sciences, Peking University, and NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China. daihui@bjmu.edu.cn.
Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China. daihui@bjmu.edu.cn.

Xiaoyan Qiu (X)

Department of Immunology, School of Basic Medical Sciences, Peking University, and NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China. qiuxy@bjmu.edu.cn.
Key Laboratory of Molecular Immunology, Chinese Academy of Medical Sciences, Beijing, China. qiuxy@bjmu.edu.cn.

Classifications MeSH